Transarterial chemoembolization alone or followed by bevacizumab for treatment of colorectal liver metastases.

ABSTRACT:

Aims

Bevacizumab (B) in association with systemic chemotherapy is commonly used for the treatment of colorectal cancer liver metastases. The aim of this study was to monitor tumor response, overall survival (OS) and progression-free survival (PFS) of patients with colorectal cancer liver metastases treated with transarterial chemoembolization (TACE) + B compared with TACE alone and to correlate the results with KRAS mutational status.

Patients & methods

This was an observational multicentric case-control study (NCT03732235) on the efficacy and safety of B administered after TACE.

Results

The disease control rate was significantly higher for the TACE + B than the TACE alone group (p < 0.001). KRAS wild-type patients had a significantly better disease cont

SUBMITTER: Fiorentini G 

PROVIDER: S-EPMC8577510 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature